fbpx

Prof. Dr. Ercüment Ovalı

Prof. Dr. Ercüment Ovalı

Bıography

He was born in Kırklareli, Turkey in 1961. He started his medical education in Hacettepe
Medical School and continued his education in 19 Mayis University. After he graduated in
1985, he specialised in Internal Medicine, in 1991 at the same university. He completed his
Sub-specialization training in the field of Hematology in 1998 at Marmara University. Ovalı,
who started his academic career in Karadeniz Technical University, Internal Medicine
Department in 1992, became Associate Professor in 1994 and Professor in 1999. He was the
chairman of the Internal Medicine Department and Bone Marrow Transplant Unit in
Karadeniz Technical University. In 2003, he worked as the project coordinator in the
foundation of the first GMP facility in Trabzon, Karadeniz Technical University. From 2007 to
2010; as the project manager of the first GMP facility of international standards for cellular
therapies in Turkey, he brought 14 different cellular treatment products, especially
mesenchymal stem cell therapy to our country.
On December 1, 2010, he was appointed as the director of Acibadem Labcell cell laboratory
and Cord Blood Bank. He still continues his duties as a director in Acibadem Hospital
Altunizade Stem Cell Clinic, Acibadem Labcell Cell and Cord Blood Laboratories, also HLA
Tissue Typing Laboratories and work Acibadem Altunizade Hospital Bone Marrow
Transplantation Center. He had published more than 350 publications, 69 of which are
overseas, have a citation rate of 5.7.
He also served as a member of the Ministry of Health’s Bone Marrow Transplantation
Commission and as a chairman of the Coordination Council for Cord Blood Banks. He has
been a board member of TUBA stem cell since 2013, and a member of TUSEB Cancer
Advisory Board since 2017.
34 different cellular treatment products developed and launched by the Ovali as of today,
including artificial skin (DermoTürk; received the best experimental study award in the USA
in 2017) and 4 other tissue engineering products. There are currently 6 patent applications.
His research of interests are cancer immunotherapy applications, and graft engineering in
bone marrow transplantations. Other ongoing studies are virus-specific T cells and
genetically modified T and NK cells (CAR-T cell / CAR-NK92). He has also been working on
gene therapy in Thalassemia, Sickle cell, and in DMD diseases. His recent research studies
include complete cloning and artificial uteruse for ex vivo embryogenesis.

PUBLICATIONS

Tastan C, Yurtsever B, Sir G, Dilek Kancagi D, Demir S, Abanuz S, Seyis U, Yildirim M,
Kuzay R, Elibol O, Arbak S, Acikel Elmas M, Birdogan S, Sahin E, Ozcan O, Sezerman U,
Ovali E. SARS-CoV-2 Isolation and Propagation from Turkish COVID-19 patients. BioRxiv
April 2020. doi: https://doi.org/10.1101/2020.04.23.056309.
Yalcin K., Ovali E., Ozdamarlar U., Celen S., Karasu G., Yesilipek A. & Hazar V. NK-92
cellular therapy for pediatric relapsed/refractory Ewing sarcoma.International Cancer
Conference Journal (2020).
Celilova S, Toret E, Adaklı Aksoy B, Ovalı E, Bozkurt C. CMV Specific T Cells for Treatment
of CMV Infection After Hematopoietic Stem Cell Transplantation in a Pediatric Case: First
Application in Turkey. 2020 Feb 20;37(1):65-67.
Batioglu-Karaaltin A, Ovali E, Karaaltin MV, Yener M, Yılmaz M, Eyüpoğlu F, Yılmaz YZ,
Bozkurt ER, Demir N, Konuk E, Bozdağ ES, Yiğit Ö, Cansiz H. Decellularization of Trachea
With Combined Techniques for Tissue-Engineered Trachea Transplantation. Clin Exp
Otorhinolaryngol. 2019 Feb;12(1):86-94.
Erbey F, Akçay A, Atay D, Ovalı E, Öztürk G. Comparison of outcomes after HLA-matched
unrelated and αβ T-cell-depleted haploidentical hematopoietic stem cell transplantation for
children with high-risk acute leukemia. Pediatr Transplant. 2018 Jun;22(4):e13192.
Batioglu-Karaaltin A, Karaaltin MV, Oztel ON, Ovali E, Sener BM, Adatepe T, Yigit O,
Bozkurt E, Baydar SY, Bagirova M, Uzun N, Allahverdiyev A. Human olfactory stem cells for
injured facial nerve reconstruction in a rat model. Head Neck. 2016 Apr;38 Suppl 1:E2011-
20.
Erbey F, Atay D, Akcay A, Ovali E, Ozturk G. Mesenchymal Stem Cell Treatment for Steroid
Refractory Graft-versus-Host Disease in Children: A Pilot and First Study from Turkey. Stem
Cells Int. 2016;2016:1641402. doi: 10.1155/2016/1641402.
Canter HI, Karaaltin MV, Ovali E, Yogun FN, Baygol EG, Kaplan S. Generation of Skin
Tissue Using Adipose Tissue-Derived Stem Cells. Ozpur MA, Guneren E, Plast Reconstr
Surg. 2016 Jan;137(1):134-43.
Akgun I, Unlu MC, Erdal OA, Ogut T, Erturk M, Ovali E, Kantarci F, Caliskan G, Akgun Y.
Matrix-induced autologous mesenchymal stem cell implantation versus matrix-induced
autologous chondrocyte implantation in the treatment of chondral defects of the knee: a 2-
year randomized study. Arch Orthop Trauma Surg. 2015 Feb;135(2):251-263.
Batioglu-Karaaltin A, Karaaltin MV, Ovali E, Yigit O, Kongur M, Inan O, Bozkurt E, Cansiz H.
In vivo tissue-engineered allogenic trachea transplantation in rabbits: a preliminary report.
Stem Cell Rev Rep. 2015 Apr;11(2):347-56.
Cakmak O, Babakurban ST, Akkuzu HG, Bilgi S, Ovalı E, Kongur M, Altintas H, Yilmaz B,
Bilezikçi B, Celik ZY, Yakicier MC, Sahin FI. Injectable tissue-engineered cartilage using
commercially available fibrin glue. Laryngoscope. 2013 Dec;123(12):2986-92..
Uçar F, Sönmez M, Erkut N, Balcı M, Yücel B, Yılmaz M, Erduran E, Ovalı E. Relation of
HLA-A, -B, -DRB1 alleles and haplotypes in patients with acute leukemia: a case control
study. Arch Med Res. 2011 May;42(4):305-10.
Sonmez M, Saglam F, Karahan SC, Erkut N, Mentese A, Sonmez B, Ucar F, Topbas
M, Ovali E. Treatment related changes in antifibrinolytic activity in patients with polycythemia
vera. Hematology. 2010 Dec;15(6):391-6.
Atasoy A, Sevim Y, Kaya I, Yilmaz M, Durmus A, Sonmez M, Omay SB, Ozdemir F, Ovali E.
The effects of electromagnetic fields on peripheral blood mononuclear cells in vitro. Bratisl
Lek Listy. 2009;110(9):526-9.
Sayitoglu M, Haznedaroğlu IC, Hatirnaz O, Erbilgin Y, Aksu S, Koca E, Adiguzel C, Bayik M,
Akalin I, Gülbas Z, Akay M, Unal A, Kaynar L, Ovali E, Yilmaz M, Yenerel M, Dagdas S,
Ozet G, Ar C, Aydin Y, Soysal T, Durgun B, Ozcebe O, Tukun A, Ilhan O, Ozbek U. Effects
of imatinib mesylate on renin-angiotensin system (RAS) activity during the clinical course of
chronic myeloid leukaemia. J Int Med Res. 2009 Jul-Aug;37(4):1018-28.
Sonmez M, Akagun T, Cobanoglu U, Topbas M, Erkut N, Yilmaz M, Ovali E, Omay SB.
Effect of LMO2 protein expression on survival in chronic myeloid leukemia patients treated
with imatinib mesylate. Hematology. 2009 Aug;14(4):220-3.
Sonmez M, Arslan M, Cobanoglu U, Kavgaci H, Ozbas HM, Aydin F, Ovali E, Omay SB.
Association of gastrointestinal stromal tumor and acute myeloid leukemia preceded by
myelodysplastic syndrome with refractory anemia. Tumori. 2009 Mar-Apr;95(2):240-2.
Uzun Y, Akdogan E, Ozdemir F, Ovali E. The effects of heparin on DLD-1 colon cancer cell
line. Bratisl Lek Listy. 2009;110(1):3-6.
Kozanoglu I, Boga C, Ozdogu H, Maytalman E, Ovali E, Sozer O. A detachment technique
based on the thermophysiologic responses of cultured mesenchymal cells exposed to cold.
Cytotherapy. 2008;10(7):686-9. doi: 10.1080/14653240802419294.
.
Effect of pathologic fractures on survival in multiple myeloma patients: a case control study.
Sonmez M, Akagun T, Topbas M, Cobanoglu U, Sonmez B, Yilmaz M, Ovali E, Omay SB.
J Exp Clin Cancer Res. 2008 Jun 10;27:11.
Sonmez M, Cobanoglu U, Ovali E, Omay SB. Use of dasatinib in the patient with
Philadelphia chromosome-positive acute lymphoblastic leukaemia with resistance to imatinib
and renal failure. J Clin Pharm Ther. 2008 Jun;33(3):329-30.
Sonmez M, Bektas O, Yilmaz M, Durmus A, Akdogan E, Topbas M, Erturk M, Ovali E, Omay
SB. The relation of lymphoma and hepatitis B virus/hepatitis C virus infections in the region
of East Black Sea, Turkey. Tumori. 2007 Nov-Dec;93(6):536-9.
Yilmaz M, Ovali E, Akdogan E, Durmus A, Sonmez M, Dikmen T, Omay SB. Autologous
serum is more effective than fetal bovine serum on proliferation of bone marrow derived
human mesenchymal stem cells. Saudi Med J. 2008 Feb;29(2):306-9.
Sonmez M, Ovali E, Omay SB. Tumor lysis syndrome during treatment with AMN107
(Nilotinib) in a patient with chronic myelogenous leukemia accelerated phase. J Clin Pharm
Ther. 2008 Feb;33(1):91-2.
Yilmaz M, Dikmen T, Sonmez M, Akdogan E, Durmus A, Omay SB, Ovali E. Change of
coagulation parameters after double plateletpheresis. Transfus Apher Sci. 2007
Oct;37(2):161-3. Epub 2007 Oct 23.
Ovali E, Dikmen T, Sonmez M, Yilmaz M, Unal A, Dalbasti T, Kuzeyli K, Erturk M, Omay SB.
Active immunotherapy for cancer patients using tumor lysate pulsed dendritic cell vaccine: a
safety study. J Exp Clin Cancer Res. 2007 Jun;26(2):209-14.
Sonmez M, Ovali E, Dikmen T, Yilmaz M, Erturk M, Sonmez B, Omay SB. The role of
hepatocyte growth factor in the differentiation of dendritic cells from peripheral blood
monocytes. Saudi Med J. 2007 May;28(5):688-95.
Sonmez M, Aydin K, Durmus A, Sucu N, Yilmaz M, Akdogan E, Koksal I, Ovali E, Omay SB.
Plasma activity of thrombin activatable fibrinolysis inhibitor in Crimean-Congo hemorrhagic
fever. J Infect. 2007 Aug;55(2):184-7.
Erem C, Deger O, Ovali E, Barlak Y. The effects of royal jelly on autoimmunity in Graves’
disease. Endocrine. 2006 Oct;30(2):175-83.
Caylan R, Bektas D, Dikmen T, Bektas O, Omay SB, Ovali E. Mesenchymal stem cells in
iatrogenic facial nerve paralysis: a possible role in the future. Eur Arch Otorhinolaryngol.
2006 Oct;263(10):963-7.
Kavgaci H, Ozdemir F, Ovali E, Yavuz A, Yavuz M, Aydin F. Effect of the farnesyl
transferase inhibitor L-744,832 on the colon cancer cell line DLD-1 and its combined use with
radiation and 5-FU. Chemotherapy. 2005 Oct;51(6):319-23.
Kaynar K, Ulusoy S, Ovali E, Vanizor B, Dikmen T, Gul S. TGF-beta and TNF-alpha
producing effects of losartan and amlodipine on human mononuclear cell culture.
Nephrology (Carlton). 2005 Oct;10(5):478-82.
Çetiner M, Fıratlı Tuğlular T, Özen Al Ahdab Y, Al Ahdab H, Köse M, Noyan F, Adıgüzel C,
Ovalı E, Bayık M. Amifostine treatment in patients with myelodysplastic syndrome. Turk J
Haematol. 2005 Sep 5;22(3):117-23.
Ağaoğlu N, Türkyilmaz S, Ovali E, Uçar F, Ağaoğlu C. Prevalence of prothrombotic
abnormalities in patients with acute mesenteric ischemia. World J Surg. 2005
Sep;29(9):1135-8.
Aliyazicioglu Y, Deger O, Ovali E, Barlak Y, Hosver I, Tekelioglu Y, Karahan SC.Effects of
Turkish pollen and propolis extracts on respiratory burst for K-562 cell lines. Int
Immunopharmacol. 2005 Oct;5(11):1652-7.
Uçar F, Ovali E, Pakdemir A, Alver A, Gök I, Karti SS, Kalay E. HLA alleles and haplotypes
in the east Black Sea Turkish population. Transplant Proc. 2004 Nov;36(9):2610-4.
Erem C, Hacihasanoğlu A, Celik S, Ovali E, Ersöz HO, Ukinç K, Deger O, Telatar M.
Coagulation and fibrinolysis parameters in type 2 diabetic patients with and without diabetic
vascular complications. Med Princ Pract. 2005 Jan-Feb;14(1):22-30.
Sonmez M, Sonmez B, Eren N, Yilmaz M, Karti SS, Ovali E. Effects of interferon-alpha-2a
on Th3 cytokine response in multiple myeloma patients. Tumori. 2004 Jul-Aug;90(4):387-9.
Alver A, Uçar F, Keha EE, Kalay E, Ovali E. Effects of leptin and insulin on CA III expression
in rat adipose tissue. J Enzyme Inhib Med Chem. 2004 Jun;19(3):279-81.
Karti SS, Odabasi Z, Korten V, Yilmaz M, Sonmez M, Caylan R, Akdogan E, Eren N, Koksal
I, Ovali E, Erickson BR, Vincent MJ, Nichol ST, Comer JA, Rollin PE, Ksiazek TG. Crimean-
Congo hemorrhagic fever in Turkey. Emerg Infect Dis. 2004 Aug;10(8):1379-84.
Ulusoy S, Ovali E, Aydin F, Erem C, Ozdemir F, Kaynar K. Hemostatic and fibrinolytic
response to nasal desmopressin in hemodialysis patients. Med Princ Pract. 2004 Nov-
Dec;13(6):340-5.
Alver A, Keha EE, Uçar F, Ovali E. The effect of carbonic anhydrase inhibition on leptin
secretion by rat adipose tissue. J Enzyme Inhib Med Chem. 2004 Apr;19(2):181-4.
Ozdemir F, Esen N, Ovali E, Tekelioglu Y, Yilmaz M, Aydin F, Kavgaci H, Boruban C. Effects
of dexamethasone, all-trans retinoic acid, vitamin D(3) and interferon-alpha on FO myeloma
cells. Chemotherapy. 2004 Oct;50(4):190-3. Epub 2004 Sep 3.
Ozdemir F, Ovali E, Aydin F, Kavgaci H, Büyükcelik A, Ucar F, Sönmez M. The in-vitro
effects of medroxyprogesterone acetate on acidic pH induced apoptosis of periferal blood
mononuclear cells. J Exp Clin Cancer Res. 2004 Mar;23(1):93-5.
Uçar F, Sönmez M, Ovali E, Ozmenoglu M, Karti SS, Yilmaz M, Pakdemir A. MTHFR C677T
polymorphism and its relation to ischemic stroke in the Black Sea Turkish population.
Am J Hematol. 2004 May;76(1):40-3.
Uçar F, Celik S, Ovali E, Karti SS, Pakdemir A, Yilmaz M, Onder E. Coexistence of
prothrombic risk factors and its relation to left ventricular thrombus in acute myocardial
infarction. Acta Cardiol. 2004 Feb;59(1):33-9.
Karti SS, Ovali E, Ozgur O, Yilmaz M, Sonmez M, Ratip S, Ozdemir F. Induction of
apoptosis and inhibition of growth of human hepatoma HepG2 cells by heparin.
Hepatogastroenterology. 2003 Nov-Dec;50(54):1864-6.
Ozgür O, Hacihasanoğlu A, Karti SS, Ovali E. Nimesulide-induced fulminant hepatitis. Turk J
Gastroenterol. 2003 Sep;14(3):208-10.
Kartı SS, Eren N, Sönmez M, Yılmaz M, Çobanoğlu Ü, Kavgacı H, Bozkaya H, Ovalı E.
Leiomyosarcoma of the Uterus Presenting with Thrombotic Thrombocytopenic Purpura. Turk
J Haematol. 2003 Sep 5;20(3):163-5.
Karti S, Yilmaz M, Sonmez M, Akdogan R, Ersoz S, Ucar F, Ovali E. Philadelphia negative,
Bcr-Abl positive chronic myeloid leukemia associated with pure red cell aplasia. J Exp Clin
Cancer Res. 2003 Jun;22(2):341-2.
Kartı SS, Ratıp S, Yılmaz M, Ukınç K, Örem A, Adıgüzel C, Dane F, Kandemir N, Ovalı E,
Bayık M.Therapeutic Trial of Cobalamin in Patients with Normal Serum Cobalamin Levels
and Predicted Cobalamin Deficiency. Turk J Haematol. 2003 Jun 5;20(2):69-74.
Karti SS, Yilmaz M, Kosucu P, Altun E, Kesen J, Arslan M, Ozgur O, Ovali E. Early medical
treatment is life saving in acute Budd-Chiari due to polycythemia vera.
Hepatogastroenterology. 2003 Mar-Apr;50(50):512-4.
Ovali E, Ratip S, Ozmenoglu M, Karti SS, Uçar F, Ukinç K, Yilmaz M, Koşucu P. Large
volume donor plasmapheresis in inherited thrombophilia implicated in arterial thrombosis.
Transfus Apher Sci. 2003 Jun;28(3):201-6.
Ovali E, Ozdemir F, Aydin F, Kavgaci H, Tekelioglu Y, Büyükcelik A, Yilmaz M. The effects
of dexamethasone on leukemic cells derived from patients with AML.
J Exp Clin Cancer Res. 2003 Mar;22(1):85-9.
Erdöl C, Ovali E, Baykan M. Granulocytic sarcoma presenting as a right atrial mass. Acta
Cardiol. 2003 Apr;58(2):155-8.
Bilici M, Tekelioğlu Y, Efendioğlu S, Ovali E, Ulgen M. The influence of olanzapine on
immune cells in patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry.
2003 May;27(3):483-5.
Kartí SS, Ovalí E, Ratip S, Cetiner M, Direskeneli H, Bayik M, Akoğlu T. Effect of interferonalpha(
2a) on neutrophil adhesion and phagocytosis in chronic myeloid leukemia and
Behçet’s disease. Clin Rheumatol. 2002 Jun;21(3):211-4.
Baykan M, Celik S, Uçar F, Kaplan S, Ovali E, Erdöl C. Effects of factor V Leiden mutations
on prognosis in patients with acute myocardial infarction.Anadolu Kardiyol Derg. 2001
Dec;1(4):242-5; AXIV. Turkish.
Kartı SS, Yılmaz M, Altun E, Koşucu P, Arslan M, Ovalı E. Polycythemia Vera Presenting
with Fulminant Hepatic Failure Due to Acute Budd-Chiari Syndrome: Case Report.
Turk J Haematol. 2002 Mar 5;19(1):43-5.
Celik S, Ovali E, Baykan M, Uçar F, Erdöl C, Durmuş I, Kaplan S. Factor V Leiden and its
relation to left ventricular thrombus in acute myocardial infarction. Acta Cardiol. 2001
Feb;56(1):1-6.
Ilhan O, Uskent N, Arslan O, Arat M, Ozkalemkaş F, Oztürk G, Kalayoglu SB, Ozet A,
Tombuloglu M, Arpaci F, Ovali E, Anak S. National survey of hemapheresis practice in
Turkey (1998). Transfus Sci. 2000 Jun;22(3):195-201.
Ovali E, Ratip S, Kibaroglu A, Tekelioglu Y, Cetiner M, Karti S, Aydin F, Bayik M, Akoglu T.
Role of hepatocyte growth factor in the development of dendritic cells from CD34+ bone
marrow cells. Haematologica. 2000 May;85(5):464-9.
Doğan IV, Ovali E, Eti Z, Yayci A, Göğüş FY. The in vitro effects of isoflurane, sevoflurane,
and propofol on platelet aggregation. Anesth Analg. 1999 Feb;88(2):432-6.
Kapicioğlu S, Baki A, Tekelioğlu Y, Arslan M, Sari M, Ovali E. The inhibiting effect of cola on
gastric mucosal cell cycle proliferation in humans. Scand J Gastroenterol. 1998
Jul;33(7):701-3.
Kapîcîoglu S, Sentürk O, Ilgün K, Ovali E. Effect of long-acting somatostatin analogue
(octreotide, SMS 201-995) plus calcium channel blocker (verapamil) on gallbladder
contraction. Hepatogastroenterology. 1998 Mar-Apr;45(20):420-3.
Aydin F, Ulusoy S, Ovali E. Results of treatment with cyclophosphamide, doxorubicin,
vincristine and prednisone (CHOP) for non-Hodgkin’s aggressive lymphoma analyzed
according to the International Prognostic Index. J Chemother. 1997 Dec;9(6):446-51.
Başlar Z, Aktuglu G, Bolaman Z, Büyükkeçeci F, Gezer S, Kansu E, Koçak R, Ovali E,
Ruacan S, Sargin D, Tunali A, Tüzüner N, Ulkü B. Incidence of aplastic anemia in Turkey: a
hospital-based prospective multicentre study. Leuk Res. 1997 Nov-Dec;21(11-12):1135-9.
Aydin F, Ulusoy S, Ovali E, Sonmez M. Effect of high-dose medroxyprogesterone acetate on
tumor necrosis factor-alpha release in patients with chemotherapy-induced neutropenia.
J Chemother. 1997 Oct;9(5):377-81.
Kapicioğlu S, Gökce E, Kapicioğlu Z, Ovali E. Treatment of migraine attacks with a longacting
somatostatin analogue (octreotide, SMS 201-995). Cephalalgia. 1997 Feb;17(1):27-
30.
Orem A, Değer O, Memiş O, Bahadir S, Ovali E, Cimşit G. Lp(a) lipoprotein levels as a
predictor of risk for thrombogenic events in patients with Behçet’s disease. Ann Rheum Dis.
1995 Sep;54(9):726-9.
Ulsoy H, Erciyes N, Ovali E, Kalac N, Ulusoy S, Albayrak D. Anesthesia in Che’diak-Higashi
syndrome–case report. Middle East J Anaesthesiol. 1995 Feb;13(1):101-5.
Mustafa NA, Yandi M, Turgutalp H, Ovali E, Aydemir V, Albayrak L. Role of diltiazem in
ischemia-reperfusion injury of the intestine. Eur Surg Res. 1994;26(6):335-41.